1. Pink Sheet
  2. >>Product Reviews

EU Decision Time On Broader Indication For AbbVie’s Skyrizi

Verdict Also Due On Expanding Olumiant’s Use As COVID-19 Treatment

 
• By Vibha Sharma

The European Medicines Agency is meeting this week to consider applications to broaden the use of approved drugs to include new indications in the EU. 

Medical form with diagnosis psoriatic arthritis on a table
About A Third Of People With Psoriasis Develop Psoriatic Arthritis • Source: Shutterstock

AbbVie could learn this week whether the European Medicines Agency will recommend EU approval to extend the indication of Skyrizi (risankizumab) to include use of the blockbuster plaque psoriasis drug as a treatment for active psoriatic arthritis in adults.

Also, the EMA is set to decide whether Eli Lilly’s immunosuppressant Olumiant (baricitinib) should be recommended for use as a treatment for COVID-19 in certain patients. Olumiant is currently...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Product Reviews

More from Pink Sheet

Non-User Fee Dollars Increased In US FDA’s Updated FY 2026 Budget Request

 
• By Derrick Gingery

The budget authority total, which is significantly higher than the amount floated in an April OMB draft document, suggests there may have been successful lobbying to increase FDA funding.

US ‘Most Favored Nation’ Pricing Could be Game Changer for Drug Access In Germany

 
• By Francesca Bruce

In this first in a series of articles looking at the potential impact of the MFN drug pricing policy on European pharmaceutical markets, EUCOPE’s Alexander Natz tells the Pink Sheet why the US policy underscores the importance of confidential net pricing.

ICH Targets RWE, Rare Diseases, Biosimilars, ATMPs In New Guideline Push

 
• By Vibha Sharma

The International Council for Harmonisation has identified four new topics that can benefit from global regulatory alignment, with timelines for initiating work to be determined later.